30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice

Roberto Coccurello, Daniela Brina, Antonio Caprioli, Roberto Conti, Orlando Ghirardi, Filippo Schepis, Anna Moles

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The aim of this study was to model in mice the association between metabolic syndrome and the administration of atypical antipsychotic (AAP). Two dosages (4 and 8 mg/kg per day) of olanzapine (OL) were infused in 36 female mice for 30 days by osmotic mini-pumps. This study was also designed to further extend the implications raised in other experiments by our model of AAP-induced metabolic dysregulation. Through the use of the osmotic mini-pumps, this model is aimed to circumvent the shorter (than in humans) half-life of AAPs in rodents and to chronically administer OL by a reliable and less disturbing method. Indirect calorimetry was used to evaluate metabolic rate (MR) and respiratory exchange ratio together with weight and caloric intake. Serum insulin, leptin, and glucose tolerance (oral glucose tolerance test) were assessed. Pancreatic beta cells insulin levels, periuterine and liver fat content were also analyzed. Olanzapine-infused mice exhibited a reduction of overall MR (kilojoule per hour) and resting MR and respiratory exchange ratio, with periuterine fat significantly enlarged. All metabolic alterations were detected at the highest dose, with major effects found on weight gain and hyperphagia. Impaired glucose metabolism, associated with hyperinsulinemia and hyperleptinemia were found. Insulin resistance was evidenced by the raise of HOMA-IR index. Increased insulin and lipid storage were detected at pancreatic and hepatic levels respectively. These findings illustrate the development of a cluster of risk factors (metabolic syndrome) and, for the first time, a decrease of energy expenditure (MR) due to chronic OL infusion.

Original languageEnglish
Pages (from-to)576-583
Number of pages8
JournalJournal of Clinical Psychopharmacology
Volume29
Issue number6
DOIs
Publication statusPublished - Dec 2009

Fingerprint

olanzapine
Glucose Intolerance
Dyslipidemias
Insulin Resistance
Insulin
Antipsychotic Agents
Fats
Glucose
Basal Metabolism
Hyperphagia
Indirect Calorimetry
Liver
Insulin-Secreting Cells
Hyperinsulinism
Glucose Tolerance Test
Respiratory Rate
Leptin
Energy Intake
Energy Metabolism
Weight Gain

Keywords

  • Energy expenditure
  • Leptin resistance
  • Metabolic syndrome
  • OGTT
  • Olanzapine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice. / Coccurello, Roberto; Brina, Daniela; Caprioli, Antonio; Conti, Roberto; Ghirardi, Orlando; Schepis, Filippo; Moles, Anna.

In: Journal of Clinical Psychopharmacology, Vol. 29, No. 6, 12.2009, p. 576-583.

Research output: Contribution to journalArticle

Coccurello, Roberto ; Brina, Daniela ; Caprioli, Antonio ; Conti, Roberto ; Ghirardi, Orlando ; Schepis, Filippo ; Moles, Anna. / 30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice. In: Journal of Clinical Psychopharmacology. 2009 ; Vol. 29, No. 6. pp. 576-583.
@article{b186a0f028354a44bbfb319a3009b141,
title = "30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice",
abstract = "The aim of this study was to model in mice the association between metabolic syndrome and the administration of atypical antipsychotic (AAP). Two dosages (4 and 8 mg/kg per day) of olanzapine (OL) were infused in 36 female mice for 30 days by osmotic mini-pumps. This study was also designed to further extend the implications raised in other experiments by our model of AAP-induced metabolic dysregulation. Through the use of the osmotic mini-pumps, this model is aimed to circumvent the shorter (than in humans) half-life of AAPs in rodents and to chronically administer OL by a reliable and less disturbing method. Indirect calorimetry was used to evaluate metabolic rate (MR) and respiratory exchange ratio together with weight and caloric intake. Serum insulin, leptin, and glucose tolerance (oral glucose tolerance test) were assessed. Pancreatic beta cells insulin levels, periuterine and liver fat content were also analyzed. Olanzapine-infused mice exhibited a reduction of overall MR (kilojoule per hour) and resting MR and respiratory exchange ratio, with periuterine fat significantly enlarged. All metabolic alterations were detected at the highest dose, with major effects found on weight gain and hyperphagia. Impaired glucose metabolism, associated with hyperinsulinemia and hyperleptinemia were found. Insulin resistance was evidenced by the raise of HOMA-IR index. Increased insulin and lipid storage were detected at pancreatic and hepatic levels respectively. These findings illustrate the development of a cluster of risk factors (metabolic syndrome) and, for the first time, a decrease of energy expenditure (MR) due to chronic OL infusion.",
keywords = "Energy expenditure, Leptin resistance, Metabolic syndrome, OGTT, Olanzapine",
author = "Roberto Coccurello and Daniela Brina and Antonio Caprioli and Roberto Conti and Orlando Ghirardi and Filippo Schepis and Anna Moles",
year = "2009",
month = "12",
doi = "10.1097/JCP.0b013e3181bfe13e",
language = "English",
volume = "29",
pages = "576--583",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - 30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice

AU - Coccurello, Roberto

AU - Brina, Daniela

AU - Caprioli, Antonio

AU - Conti, Roberto

AU - Ghirardi, Orlando

AU - Schepis, Filippo

AU - Moles, Anna

PY - 2009/12

Y1 - 2009/12

N2 - The aim of this study was to model in mice the association between metabolic syndrome and the administration of atypical antipsychotic (AAP). Two dosages (4 and 8 mg/kg per day) of olanzapine (OL) were infused in 36 female mice for 30 days by osmotic mini-pumps. This study was also designed to further extend the implications raised in other experiments by our model of AAP-induced metabolic dysregulation. Through the use of the osmotic mini-pumps, this model is aimed to circumvent the shorter (than in humans) half-life of AAPs in rodents and to chronically administer OL by a reliable and less disturbing method. Indirect calorimetry was used to evaluate metabolic rate (MR) and respiratory exchange ratio together with weight and caloric intake. Serum insulin, leptin, and glucose tolerance (oral glucose tolerance test) were assessed. Pancreatic beta cells insulin levels, periuterine and liver fat content were also analyzed. Olanzapine-infused mice exhibited a reduction of overall MR (kilojoule per hour) and resting MR and respiratory exchange ratio, with periuterine fat significantly enlarged. All metabolic alterations were detected at the highest dose, with major effects found on weight gain and hyperphagia. Impaired glucose metabolism, associated with hyperinsulinemia and hyperleptinemia were found. Insulin resistance was evidenced by the raise of HOMA-IR index. Increased insulin and lipid storage were detected at pancreatic and hepatic levels respectively. These findings illustrate the development of a cluster of risk factors (metabolic syndrome) and, for the first time, a decrease of energy expenditure (MR) due to chronic OL infusion.

AB - The aim of this study was to model in mice the association between metabolic syndrome and the administration of atypical antipsychotic (AAP). Two dosages (4 and 8 mg/kg per day) of olanzapine (OL) were infused in 36 female mice for 30 days by osmotic mini-pumps. This study was also designed to further extend the implications raised in other experiments by our model of AAP-induced metabolic dysregulation. Through the use of the osmotic mini-pumps, this model is aimed to circumvent the shorter (than in humans) half-life of AAPs in rodents and to chronically administer OL by a reliable and less disturbing method. Indirect calorimetry was used to evaluate metabolic rate (MR) and respiratory exchange ratio together with weight and caloric intake. Serum insulin, leptin, and glucose tolerance (oral glucose tolerance test) were assessed. Pancreatic beta cells insulin levels, periuterine and liver fat content were also analyzed. Olanzapine-infused mice exhibited a reduction of overall MR (kilojoule per hour) and resting MR and respiratory exchange ratio, with periuterine fat significantly enlarged. All metabolic alterations were detected at the highest dose, with major effects found on weight gain and hyperphagia. Impaired glucose metabolism, associated with hyperinsulinemia and hyperleptinemia were found. Insulin resistance was evidenced by the raise of HOMA-IR index. Increased insulin and lipid storage were detected at pancreatic and hepatic levels respectively. These findings illustrate the development of a cluster of risk factors (metabolic syndrome) and, for the first time, a decrease of energy expenditure (MR) due to chronic OL infusion.

KW - Energy expenditure

KW - Leptin resistance

KW - Metabolic syndrome

KW - OGTT

KW - Olanzapine

UR - http://www.scopus.com/inward/record.url?scp=72949088255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949088255&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e3181bfe13e

DO - 10.1097/JCP.0b013e3181bfe13e

M3 - Article

C2 - 19910724

AN - SCOPUS:72949088255

VL - 29

SP - 576

EP - 583

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 6

ER -